SCHEMBL3085967

SCHEMBL3085967

CCN(CC)C(=O)C(Cc1cccc(NC(=O)c2ccccc2)c1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLG P00747 2/20 0.46
PTGES O14684 1/20 0.43
LARS1 Q9P2J5 1/20 0.43
KAT6A Q92794 2/20 0.43
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42
CASP3 P42574 1/20 0.42
RAB9A P51151 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GPR27 Q9NS67 1/20 0.42
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3093901 0.91 MMP9 (0.46) PLGLARS1KAT6ANPC1RAB9A
SCHEMBL3102970 0.91 MMP9 (0.46) PLGLARS1KAT6ANPC1RAB9A
SCHEMBL3093089 0.88 KDR (0.51) LARS1NPC1RAB9ALMNATSHR
SCHEMBL3085973 0.87 LARS1 (0.53) PLGLARS1MEN1LMNAKMT2A
SCHEMBL15000177 0.87 LARS1 (0.44) PLGLARS1KAT6AMEN1KMT2A
SCHEMBL14999923 0.85 MAPT (0.46) LARS1NPC1RAB9AMEN1LMNA
SCHEMBL3092720 0.85 MEN1 (0.53) LARS1KAT6ANPC1POLBCASP3
SCHEMBL3093128 0.85 FADS1 (0.42) PLGLARS1KAT6ANPC1CASP3
SCHEMBL3096740 0.85 LARS1 (0.41) PLGLARS1KAT6ANPC1RAB9A
SCHEMBL3090792 0.85 NPC1 (0.51) LARS1KAT6ANPC1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 PLG 2448/4885PTGES 1099/4885LARS1 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.